-
Posted by
Two Blokes Jul 16 -
Filed in
Stock
-
2 views
AstraZeneca on Wednesday said that its experimental drug anselamimab did not meet the main goal of a late-stage study for the treatment of AL amyloidosis, a rare condition that causes a buildup of protein deposits in the body.
